James R Klinger

List of Publications by Year in Descending Order

73 papers	2,477 citations	28 h-index	49 g-index
81 ext. papers	3,201 ext. citations	5.5 avg, IF	5.2 L-index

#	Paper	IF	Citations
73	Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.. *Pulmonary Circulation*, **2022**, 12, e12055	2.7	0
72	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. *Lancet Respiratory Medicine,the*, **2021**, 9, 573-584	35.1	22
71	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. *Pulmonary Circulation*, **2021**, 11, 20458940211020913	2.7	3
70	Riociguat: Clinical research and evolving role in therapy. *British Journal of Clinical Pharmacology*, **2021**, 87, 2645-2662	3.8	7
69	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. *European Respiratory Journal*, **2021**, 57,	13.6	7
68	Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 761-764	10.2	3
67	Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension. *Annals of the American Thoracic Society*, **2021**, 18, 218-228	4.7	5
66	Effect of dose, dosing intervals, and hypoxic stress on the reversal of pulmonary hypertension by mesenchymal stem cell extracellular vesicles.. *Pulmonary Circulation*, **2021**, 11, 20458940211046137	2.7	1
65	Novel Pharmacological Targets for Pulmonary Arterial Hypertension. *Comprehensive Physiology*, **2021**, 11, 2297-2349	7.7	1
64	Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. *International Journal of Cardiology*, **2020**, 317, 188-192	3.2	3
63	Rapid development of pulmonary hypertension and right ventricular failure due to large vessel intravascular microcrystalline cellulosis in an intravenous drug user. *Pulmonary Circulation*, **2020**, 10, 2045894020907871	2.7	3
62	Alternative Splicing of the Cardiac Sodium Channel in Pulmonary Arterial Hypertension. *Chest*, **2020** , 158, 735-738	5.3	5
61	Culture of pulmonary artery endothelial cells from pulmonary artery catheter balloon tips: considerations for use in pulmonary vascular disease. *European Respiratory Journal*, **2020**, 55,	13.6	5
60	Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in Rats. *American Journal of Respiratory Cell and Molecular Biology*, **2020**, 62, 577-587	5.7	28
59	Guidelines for the Treatment of Pulmonary Arterial Hypertension. *Lung*, **2020**, 198, 581-596	2.9	16
58	Prevalence and risk factors of pulmonary hypertension among adult patients with HIV infection in Ethiopia. *Pulmonary Circulation*, **2020**, 10, 2045894020971518	2.7	0
57	Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. *Pulmonary Circulation*, **2020**, 10, 2045894020964342	2.7	1

56	Low dose 100 cGy irradiation as a potential therapy for pulmonary hypertension. *Journal of Cellular Physiology*, **2019**, 234, 21193-21198	7	4
55	Response. *Chest*, **2019**, 156, 187-188	5.3	
54	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. *Lancet Respiratory Medicine,the*, **2019**, 7, 227-238	35.1	55
53	Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. *Chest*, **2019**, 155, 565-586	5.3	126
52	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. *European Respiratory Journal*, **2019**, 53,	13.6	407
51	Chronic Thromboembolic Pulmonary Hypertension. *Heart Failure Clinics*, **2018**, 14, 339-351	3.3	6
50	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. *Chest*, **2017**, 151, 468-480	5.3	57
49	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. *Respiratory Medicine*, **2017**, 122 Suppl 1, S18-S22	4.6	13
48	The Nitric Oxide Pathway in Pulmonary Vascular Disease. *American Journal of Cardiology*, **2017**, 120, S71-S79	3	54
47	Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 360-368	10.2	61
46	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. *European Respiratory Journal*, **2017**, 50,	13.6	74
45	Ask The Expert: What Are Some Pitfalls and Promises of the Current PAH Treatment Guidelines?. *Advances in Pulmonary Hypertension*, **2017**, 15, 182-183	0.5	
44	Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation. *Pulmonary Circulation*, **2016**, 6, 191-5	2.7	15
43	Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. *Cardiovascular Research*, **2016**, 110, 319-30	9.9	142
42	Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments. *Cardiology Clinics*, **2016**, 34, 413-33	2.5	38
41	Sepsis and Pulmonary Arterial Hypertension in the ICU. *Advances in Pulmonary Hypertension*, **2015**, 13, 188-196	0.5	2
40	Modulation of cGMP Synthesis and Metabolism. *Respiratory Medicine*, **2015**, 355-375	0.2	1
39	Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. *Trials*, **2014**, 15, 502	2.8	7

38	Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. *Chest*, **2014**, 146, 449-475	5.3	200
37	Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. *JAMA - Journal of the American Medical Association*, **2014**, 312, 2135-45	27.4	34
36	Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension. *Pulmonary Circulation*, **2014**, 4, 45-52	2.7	3
35	Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 639-46	10.2	130
34	Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. *Clinics in Chest Medicine*, **2013**, 34, 811-24	5.3	4
33	Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A. *Journal of Applied Physiology*, **2013**, 114, 307-15	3.7	6
32	Initial risk assessment for pulmonary hypertension in patients with COPD. *Lung*, **2012**, 190, 83-9	2.9	13
31	WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. *Progress in Cardiovascular Diseases*, **2012**, 55, 89-103	8.5	18
30	Transfer of Monocrotaline-Induced Pulmonary Hypertension to Healthy Mice Via Microparticles. *Blood*, **2012**, 120, 5190-5190	2.2	
29	C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade. *Life Sciences*, **2011**, 89, 460-6	6.8	8
28	Tadalafil for the treatment of pulmonary arterial hypertension. *Expert Review of Respiratory Medicine*, **2011**, 5, 315-28	3.8	7
27	Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. *American Journal of Cardiology*, **2011**, 108, 302-7	3	35
26	Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. *Lung*, **2011**, 189, 207-12	2.9	30
25	Pulmonary hypertension in a stable community-based COPD population. *Lung*, **2011**, 189, 377-82	2.9	27
24	Cardiac atria are the primary source of ANP release in hypoxia-adapted rats. *Life Sciences*, **2010**, 87, 382-9	6.8	8
23	Tadalafil in Geriatric Patients With Pulmonary Arterial Hypertension. *Chest*, **2010**, 138, 367A	5.3	3
22	Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. *Drug Design, Development and Therapy*, **2009**, 3, 269-87	4.4	35
21	Marrow cell infusion attenuates vascular remodeling in a murine model of monocrotaline-induced pulmonary hypertension. *Stem Cells and Development*, **2009**, 18, 773-82	4.4	15

20	Pulmonary Arterial Hypertension in Pregnancy **2009**, 285-312		
19	Diagnosis and Management of Pulmonary Hypertension Associated With Pulmonary Fibrosis. *Advances in Pulmonary Hypertension*, **2009**, 8, 141-147	0.5	
18	The nitric oxide/cGMP signaling pathway in pulmonary hypertension. *Clinics in Chest Medicine*, **2007**, 28, 143-67, ix	5.3	66
17	Rottlerin causes pulmonary edema in vivo: a possible role for PKCdelta. *Journal of Applied Physiology*, **2007**, 103, 2084-94	3.7	25
16	Pulmonary arterial hypertension: an overview. *Seminars in Cardiothoracic and Vascular Anesthesia*, **2007**, 11, 96-103	1.4	3
15	Pulmonary hypertension in the intensive care unit: Critical role of the right ventricle. *Critical Care Medicine*, **2007**, 35, 2210-1	1.4	7
14	Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. *Experimental Cell Research*, **2006**, 312, 401-10	4.2	30
13	Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. *Chest*, **2006**, 129, 417-425	5.3	79
12	Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. *Current Opinion in Pharmacology*, **2005**, 5, 245-50	5.1	40
11	Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. *Respiratory Medicine*, **2005**, 99, 1501-10	4.6	70
10	Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension. *Chest*, **2005**, 128, 618S-619S	5.3	7
9	Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. *Experimental Biology and Medicine*, **2004**, 229, 920-5	3.7	36
8	Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 282, H58-65	5.2	35
7	Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome. *Chest*, **2002**, 121, 656-9	5.3	41
6	Inhaled nitric oxide in ARDS. *Critical Care Clinics*, **2002**, 18, 45-68, vi	4.5	26
5	Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. *Chest*, **2001**, 120, 866-72	5.3	100
4	Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **1999**, 276, L868-74	5.8	29
3	Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. *Journal of Applied Physiology*, **1998**, 84, 1646-52	3.7	45

2	C-receptor ligand blocks pulmonary clearance of atrial natriuretic peptide in isolated rat lungs. *Experimental Biology and Medicine*, **1992**, 201, 154-8	3.7	9
1	Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. *Chest*, **1991**, 99, 715-23	5.3	74